13 January 2025
13 January 2025
Medtronic’s BrainSense aDBS is a therapy intended to improve the quality of life for individuals living with Parkinson’s disease.
The investment was spearheaded by Redmile Group, with contributions from current and new investors.
The approval is backed by the SmartfIRE study.
The authorisation marks the first for a ChLIA in direct and quantitative free testosterone testing.
The collaboration licenses Emervax to use Kindeva’s microneedle array patch to administer vaccines developed using its RNA platform.
Cross-Border Impact Ventures and We Venture Capital led the funding round.
QIAstat-Dx uses real-time PCR technology to multiply genetic targets within the same reaction and deliver test results in around one hour.
Designed to optimise bone formation and cell proliferation, the product is offered in two distinct versions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
